中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
17期
2591-2594
,共4页
肾功能衰竭,慢性%纤维化%转化生长因子β1%基质金属蛋白酶1
腎功能衰竭,慢性%纖維化%轉化生長因子β1%基質金屬蛋白酶1
신공능쇠갈,만성%섬유화%전화생장인자β1%기질금속단백매1
Kidney failure,Chronic%Fibrosis%Transforming growth factor beta1%Matrix metalloproteinase 1
目的：评价三七总皂苷（PNS）对慢性肾衰竭患者肾脏纤维化的临床防治效果。方法采用随机数字表法将60例慢性肾衰竭患者分为对照组和观察组，各30例。对照组给予常规药物治疗，观察组在此基础上静脉滴注PNS葡萄糖注射液，两组均治疗2个月。比较两组治疗前后的肝纤维化（肝纤）四项、肾功能、血脂及转化生长因子β1（TGF-β1）、基质金属蛋白酶组织抑制因子（TIMP-1）表达水平的变化。结果治疗2个月后，观察组肝纤四项（t＝3．94～5．62，均P＜0．05）、肾功能（t＝4．15、4．29，均P＜0．05）、血脂（t＝3.83～5.47，均P＜0.05）及肾脏纤维化相关因子TGF-β1（t＝5．19，P＜0．01）、TIMP-1（t＝4．16，P＜0．05）均较治疗前有明显改善，对照组肝纤四项中透明质酸酶、血脂及肾脏纤维化相关因子TGF-β1、TIMP-1亦优于治疗前，观察组所有指标均较对照组变化显著。对照组和观察组总有效率分别为66．67％和83．33％，差异有统计学意义（χ2＝5.16，P＜0．05）。观察组未见不良反应。结论 PNS 可通过降低肾脏纤维化相关因子TGF-β1、TIMP-1表达水平达到改善肾脏纤维化的作用，可作为慢性肾功能衰竭常规辅助药物。
目的：評價三七總皂苷（PNS）對慢性腎衰竭患者腎髒纖維化的臨床防治效果。方法採用隨機數字錶法將60例慢性腎衰竭患者分為對照組和觀察組，各30例。對照組給予常規藥物治療，觀察組在此基礎上靜脈滴註PNS葡萄糖註射液，兩組均治療2箇月。比較兩組治療前後的肝纖維化（肝纖）四項、腎功能、血脂及轉化生長因子β1（TGF-β1）、基質金屬蛋白酶組織抑製因子（TIMP-1）錶達水平的變化。結果治療2箇月後，觀察組肝纖四項（t＝3．94～5．62，均P＜0．05）、腎功能（t＝4．15、4．29，均P＜0．05）、血脂（t＝3.83～5.47，均P＜0.05）及腎髒纖維化相關因子TGF-β1（t＝5．19，P＜0．01）、TIMP-1（t＝4．16，P＜0．05）均較治療前有明顯改善，對照組肝纖四項中透明質痠酶、血脂及腎髒纖維化相關因子TGF-β1、TIMP-1亦優于治療前，觀察組所有指標均較對照組變化顯著。對照組和觀察組總有效率分彆為66．67％和83．33％，差異有統計學意義（χ2＝5.16，P＜0．05）。觀察組未見不良反應。結論 PNS 可通過降低腎髒纖維化相關因子TGF-β1、TIMP-1錶達水平達到改善腎髒纖維化的作用，可作為慢性腎功能衰竭常規輔助藥物。
목적：평개삼칠총조감（PNS）대만성신쇠갈환자신장섬유화적림상방치효과。방법채용수궤수자표법장60례만성신쇠갈환자분위대조조화관찰조，각30례。대조조급여상규약물치료，관찰조재차기출상정맥적주PNS포도당주사액，량조균치료2개월。비교량조치료전후적간섬유화（간섬）사항、신공능、혈지급전화생장인자β1（TGF-β1）、기질금속단백매조직억제인자（TIMP-1）표체수평적변화。결과치료2개월후，관찰조간섬사항（t＝3．94～5．62，균P＜0．05）、신공능（t＝4．15、4．29，균P＜0．05）、혈지（t＝3.83～5.47，균P＜0.05）급신장섬유화상관인자TGF-β1（t＝5．19，P＜0．01）、TIMP-1（t＝4．16，P＜0．05）균교치료전유명현개선，대조조간섬사항중투명질산매、혈지급신장섬유화상관인자TGF-β1、TIMP-1역우우치료전，관찰조소유지표균교대조조변화현저。대조조화관찰조총유효솔분별위66．67％화83．33％，차이유통계학의의（χ2＝5.16，P＜0．05）。관찰조미견불량반응。결론 PNS 가통과강저신장섬유화상관인자TGF-β1、TIMP-1표체수평체도개선신장섬유화적작용，가작위만성신공능쇠갈상규보조약물。
Objective To evaluate the clinical prevention and cure efficiency of panax notoginosides(PNS) in patients with chronic renal failure.Methods 60 patients with chronic renal failure were selected and randomly divided into the control group and the observation group,with 30 cases in each group by random number table.The patients in the control group underwent regular maintenance hemodialysis(MHD),while the patients in the observa-tion group were given PNS glucose injection on the base of the control group for two months treatment.Comparison was made between the two groups in the aspect of liver filament four items,renal function,blood lipids and the levels of TGF-β1 ,TIMP-1 expression for renal fibrosis.Results After two months treatment,the liver filament four items (t=3.94-5.62,all P<0.05),renal function (t=4.15,4.29,all P<0.05),blood lipids (t=3.83 -5.47,all P<0.05)and the level of TGF-β1,TIMP-1 were all significantly decreased in the observation group,while HA, blood lipids and the level of TGF-β1(t=5.19,P<0.01),TIMP-1(t=4.16,P<0.05)were also decreased in the control group.All the indexes of the observation group were much significant than those of the control group.Total effective rate of the observation group was 83.33%,which was significantly higher than 66.67% of the control group (χ2 =5.16,P<0.05).There was no adverse reaction in the observation group.Conclusion PNS could improve renal fibrosis by lowering the level of TGF-β1 and TIMP-1 ,and could be used as conventional auxiliary drug for patients with chronic renal failure.
